473 related articles for article (PubMed ID: 2507139)
1. Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes.
Wang YL; Si LS; Kanbour A; Herberman RB; Whiteside TL
Cancer Res; 1989 Nov; 49(21):5979-85. PubMed ID: 2507139
[TBL] [Abstract][Full Text] [Related]
2. Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovarian tumors.
Heo DS; Whiteside TL; Kanbour A; Herberman RB
J Immunol; 1988 Jun; 140(11):4042-9. PubMed ID: 3286766
[TBL] [Abstract][Full Text] [Related]
3. Long-term interleukin 2-dependent growth and cytotoxic activity of tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck.
Heo DS; Whiteside TL; Johnson JT; Chen KN; Barnes EL; Herberman RB
Cancer Res; 1987 Dec; 47(23):6353-62. PubMed ID: 3315186
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma.
Finke JH; Rayman P; Alexander J; Edinger M; Tubbs RR; Connelly R; Pontes E; Bukowski R
Cancer Res; 1990 Apr; 50(8):2363-70. PubMed ID: 2107973
[TBL] [Abstract][Full Text] [Related]
5. Lymphocytes infiltrating ovarian malignant ascites: modulation of IL-2-induced proliferation by IL-4 and of selective increase in CD8+ T cells by TNF-alpha.
Ioannides CG; Rashed S; Fisk B; Fan D; Itoh K; Freedman RS
Lymphokine Cytokine Res; 1991 Aug; 10(4):307-15. PubMed ID: 1932375
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.
Belldegrun A; Muul LM; Rosenberg SA
Cancer Res; 1988 Jan; 48(1):206-14. PubMed ID: 3257161
[TBL] [Abstract][Full Text] [Related]
7. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
Owen-Schaub LB; Gutterman JU; Grimm EA
Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408
[TBL] [Abstract][Full Text] [Related]
8. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
[TBL] [Abstract][Full Text] [Related]
9. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
10. Characterization of the CD4+ and CD8+ tumor infiltrating lymphocytes propagated with bispecific monoclonal antibodies.
Wong JT; Pinto CE; Gifford JD; Kurnick JT; Kradin RL
J Immunol; 1989 Nov; 143(10):3404-11. PubMed ID: 2509557
[TBL] [Abstract][Full Text] [Related]
11. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas.
Itoh K; Tilden AB; Balch CM
Cancer Res; 1986 Jun; 46(6):3011-7. PubMed ID: 3486040
[TBL] [Abstract][Full Text] [Related]
12. Characterization of human autotumor-reactive T-cell clones obtained from tumor-infiltrating lymphocytes in liver metastasis of gastric carcinoma.
Shimizu Y; Weidmann E; Iwatsuki S; Herberman RB; Whiteside TL
Cancer Res; 1991 Nov; 51(22):6153-62. PubMed ID: 1718596
[TBL] [Abstract][Full Text] [Related]
13. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets.
Ochoa AC; Hasz DE; Rezonzew R; Anderson PM; Bach FH
Cancer Res; 1989 Feb; 49(4):963-8. PubMed ID: 2521457
[TBL] [Abstract][Full Text] [Related]
14. Characterization of OKT3-initiated lymphokine-activated effectors expanded with interleukin 2 and tumor necrosis factor alpha.
Yang SC; Owen-Schaub LB; Roth JA; Grimm EA
Cancer Res; 1990 Jun; 50(12):3526-32. PubMed ID: 2160321
[TBL] [Abstract][Full Text] [Related]
15. Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells.
Kooi S; Freedman RS; Rodriguez-Villanueva J; Platsoucas CD
Lymphokine Cytokine Res; 1993 Dec; 12(6):429-37. PubMed ID: 8123759
[TBL] [Abstract][Full Text] [Related]
16. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites.
Ioannides CG; Platsoucas CD; Rashed S; Wharton JT; Edwards CL; Freedman RS
Cancer Res; 1991 Aug; 51(16):4257-65. PubMed ID: 1868446
[TBL] [Abstract][Full Text] [Related]
17. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors.
Alexander JP; Kudoh S; Melsop KA; Hamilton TA; Edinger MG; Tubbs RR; Sica D; Tuason L; Klein E; Bukowski RM
Cancer Res; 1993 Mar; 53(6):1380-7. PubMed ID: 8443817
[TBL] [Abstract][Full Text] [Related]
18. Solid-phase anti-CD3 antibody activation of murine tumor-infiltrating lymphocytes.
Massaro AF; Schoof DD; Rubinstein A; Zuber M; Leonard-Vidal FJ; Eberlein TJ
Cancer Res; 1990 May; 50(9):2587-92. PubMed ID: 2139356
[TBL] [Abstract][Full Text] [Related]
19. The effect of anti-CD3 on the induction of non-MHC restricted cytolytic activity.
Watanabe H; Narumi K; Stewart CC; Arbuck SG; Foon KA; Goldrosen MH
Anticancer Res; 1992; 12(6B):1925-33. PubMed ID: 1295440
[TBL] [Abstract][Full Text] [Related]
20. Enrichment in tumor-reactive CD8+ T-lymphocytes by positive selection from the blood and lymph nodes of patients with head and neck cancer.
Letessier EM; Heo DS; Okarma T; Johnson JT; Herberman RB; Whiteside TL
Cancer Res; 1991 Aug; 51(15):3891-9. PubMed ID: 1677310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
